NurExone Biologic Ltd., an Israeli biopharmaceutical company aiming to revolutionize the treatment of spinal cord injury (SCI), is leveraging its proprietary technologies into a platform technology company with a potentially diverse portfolio of novel, cutting-edge therapies for several CNS traumatic indications.